Drugs / GSK5926371
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07371468 | Feb 2026 → Mar 2028 expected | systemic lupus erythematosus | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07607925 | Jun 2026 → Sep 2029 expected | B-cell non-Hodgkin lymphoma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK5926371 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07607925 ↗ |
| Modality | Protein / enzyme biologic | “a CD19/CD20 T-cell Engager” NCT07371468 ↗ |
| Target | CD19 | “a CD19/CD20 T-cell Engager” NCT07371468 ↗ |